呼吁将高危代谢功能障碍相关脂肪性肝炎的诊断率提高一倍

IF 13 Q1 HEALTH CARE SCIENCES & SERVICES

Lancet Regional Health-Europe Pub Date : 2025-07-01 DOI:10.1016/j.lanepe.2025.101320

Jeffrey V. Lazarus , Paul N. Brennan , Henry E. Mark , William Alazawi , Alina M. Allen , Christopher D. Byrne , Laurent Castera , Cyrielle Caussy , Kenneth Cusi , Martin M. Grajower , Christopher J. Kopka , Jo Massoels , Michael Roden , C Wendy Spearman , Frank Tacke , Vincent Wai-Sun Wong , Mazen Noureddin

{"title":"呼吁将高危代谢功能障碍相关脂肪性肝炎的诊断率提高一倍","authors":"Jeffrey V. Lazarus , Paul N. Brennan , Henry E. Mark , William Alazawi , Alina M. Allen , Christopher D. Byrne , Laurent Castera , Cyrielle Caussy , Kenneth Cusi , Martin M. Grajower , Christopher J. Kopka , Jo Massoels , Michael Roden , C Wendy Spearman , Frank Tacke , Vincent Wai-Sun Wong , Mazen Noureddin","doi":"10.1016/j.lanepe.2025.101320","DOIUrl":null,"url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.</div></div>","PeriodicalId":53223,"journal":{"name":"Lancet Regional Health-Europe","volume":"54 ","pages":"Article 101320"},"PeriodicalIF":13.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis\",\"authors\":\"Jeffrey V. Lazarus , Paul N. Brennan , Henry E. Mark , William Alazawi , Alina M. Allen , Christopher D. Byrne , Laurent Castera , Cyrielle Caussy , Kenneth Cusi , Martin M. Grajower , Christopher J. Kopka , Jo Massoels , Michael Roden , C Wendy Spearman , Frank Tacke , Vincent Wai-Sun Wong , Mazen Noureddin\",\"doi\":\"10.1016/j.lanepe.2025.101320\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.</div></div>\",\"PeriodicalId\":53223,\"journal\":{\"name\":\"Lancet Regional Health-Europe\",\"volume\":\"54 \",\"pages\":\"Article 101320\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Regional Health-Europe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666776225001127\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Regional Health-Europe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666776225001127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

摘要

代谢功能障碍相关脂肪性肝炎（MASH）是越来越重要的发病率和死亡率的贡献者。很少强调其及时诊断和干预措施，以防止不良疾病后果。MASH结果的主要决定因素是肝纤维化阶段。肥胖和/或2型糖尿病患者的MASH患病率较高，每6名成年人中就有1人患有中度至晚期纤维化的MASH。在所研究的四个国家实现MASH诊断的范式转变将需要扩大基于社区的诊断能力，这也将促进预防工作并提供治疗和护理机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions to prevent adverse disease outcomes. The principal determinant of MASH outcomes is the liver fibrosis stage. The prevalence of MASH is higher among people living with obesity and/or type 2 diabetes, with MASH with moderate to advanced fibrosis affecting one in six adults. Delivering a paradigm shift in MASH diagnosis in the four countries studied will require an expansion of community-based diagnostic capability that will also foster prevention efforts and provide opportunities for treatment and care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Regional Health-Europe Multiple-

CiteScore

19.90

自引率

1.40%

发文量

260

审稿时长

9 weeks

期刊介绍： The Lancet Regional Health – Europe, a gold open access journal, is part of The Lancet's global effort to promote healthcare quality and accessibility worldwide. It focuses on advancing clinical practice and health policy in the European region to enhance health outcomes. The journal publishes high-quality original research advocating changes in clinical practice and health policy. It also includes reviews, commentaries, and opinion pieces on regional health topics, such as infection and disease prevention, healthy aging, and reducing health disparities.